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Abstract
Purpose To assess the clinical and economic outcomes
among patients with chemotherapy-induced anemia (CIA)
treated with United States Food and Drug Administration-
approved fixed dosing regimens of erythropoiesis-
stimulating agents (ESA).
Methods Data were employed from the Dosing and Out-
comes Study of Erythropoiesis-Stimulating Therapies
(DOSE) registry to evaluate CIA patients who were initiated
on either epoetin alfa (EPO) 40,000 Units (U) or darbepoetin
alfa (DARB) 500 micrograms(mcg) between January 1,2006
and May 8, 2009. Study measurements included ESA
treatment dose and dose ratio, changes in hemoglobin (Hb)
levels from baseline, and cumulative ESA costs.
Results Five hundred forty patients treated in 44 clinical
centers were evaluated, of which 420 were initiated on EPO
40,000 U and 120 were initiated on DARB 500 mcg. Both
cohorts had similar baseline characteristics, although EPO
patients were less likely than DARB patients to have
received iron supplementation before ESA initiation (11.4%
EPO vs. 20.0% DARB, p=0.015). The EPO-to-DARB dose
ratio based on cumulative ESA dose was 169:1 (U EPO:
mcg DARB). EPO patients showed statistically greater Hb
improvement compared to DARB patients, and compared
to EPO patients, a greater proportion of DARB patients
required a blood transfusion (13.9% EPO vs. 22.5%
DARB, p=0.026). Mean cumulative ESA cost was signif-
icantly lower for EPO patients than DARB patients ($4,261
EPO vs. $8,643 DARB, p<0.0001).
Conclusions These findings reported that patients with CIA
achieved more favorable clinical and economic outcomes if
initiated with EPO 40,000 U vs. DARB 500 mcg.
Keywords Chemotherapy-induced anemia.Erythropoiesis-
stimulating agents.Clinical outcomes.Healthcare costs
Introduction
Two erythropoiesis-stimulating agents (ESAs) have been
approved by the United States Food and Drug Administra-
tion (FDA) for the treatment of chemotherapy-induced
anemia (CIA) among cancer patients with non-myeloid
malignancies: epoetin alfa (EPO) and darbepoetin alfa
(DARB). For patients with CIA and hemoglobin levels
below 10 g/dL, the FDA has approved the treatment of
EPO at 40,000 Units (U) per week or 150 U per kg three
times weekly and DARB at 500 micrograms (mcg) every
3 weeks or 2.25 mcg per kg weekly [1, 2]. Guidelines
recommend ESAs for transfusion reduction in CIA, and
clinical trials have shown that both EPO and DARB are
effective for reducing the need for blood transfusions
among CIA patients [1–7]. The resource use and costs
associated with ESA treatments have been reported previ-
ously [8–11]. Multiple claims-based studies have reported
relative ESA utilization with some claims-based studies
reporting cumulative utilization and associated cost [9, 10].
Other such studies have imputed missing ESA data based
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Additionally, such studies are limited by the lack of clinical
data and the assumption of comparable clinical outcomes.
Thus, the objective of this study was to evaluate the
clinical and economic outcomes associated with FDA-
approved fixed initial ESA doses among CIA patients in
actual clinical practice. This is the first national, prospective,
observational study to examine the outcomes of patients who
initiated ESA treatment with either EPO 40,000 U or DARB
500 mcg. The knowledge gained from this study may help
inform healthcare providers and payers about the health and
economic outcomes associated with these dosing regimens
and patterns of care in the real world.
Methods
Data source
The Dosing and Outcomes Study of Erythropoiesis-
StimulatingTherapies(DOSE)isaprospective,observational,
multi-center registry that collected data on CIA patients
treated with ESAs between December 2003 and May 2009
[12]. This analysis employed data from the DOSE registry to
evaluate the clinical and economic outcomes of CIA patients
initiated on FDA-approved fixed doses of EPO or DARB.
Specific data obtained from this registry include baseline
demographic and clinical characteristics, ESA utilization,
and anemia-related outcomes (e.g., transfusions).
Study population
As of May 2009, the DOSE registry contained data on
2,349 adult cancer patients (aged ≥18 years) receiving EPO
or DARB who had not been treated with either agent within
the previous 90 days prior to enrolling in the registry.
Patients were excluded from the registry if they were on
dialysis for end-stage renal disease, had a diagnosis of
myelodysplasia, or were scheduled for stem cell transplan-
tation. Data collection began with the initiation of ESA
therapy and continued for either the duration of ESA
administration or 16 weeks, whichever was shorter.
The current analysis involved CIA patients initiated
between January 1, 2006 and May 8, 2009 on the FDA-
approved dosing of EPO 40,000 U or DARB 500 mcg. This
timeframe was chosen to capture patients affected by the
FDA approval of the DARB 500 mcg dosing regimen in
March 2006. Patients administered both EPO and DARB
during the study period were excluded from the analysis.
Patients were also excluded from the analysis if they had
less than two EPO or two DARB doses or did not have at
least one hemoglobin (Hb) value measured before and at least
one after initiation of EPO or DARB. Eligible patients had at
least one transfusion-independent Hb determination (defined
as a determination occurring ≥28 days after a transfusion)
occurring during the duration of ESA treatment (Fig. 1).
Measurements and analyses
Patients were categorized according to initiated ESA dosing
(EPO 40,000 U and DARB 500 mcg). All patients were
assessedatbaseline as todemographic characteristics (e.g.,age,
weight, and gender), cancer type, cancer treatment, and anemia
characteristics (e.g., Hb level and iron supplementation).
Actual utilization of EPO and DARB was evaluated
during the follow-up period with respect to administered
dose per injection, number of days between injections, dose
frequency, cumulative ESA dose, treatment duration,
number of Hb determinations, number of office visits, and
cumulative ESA cost (based on the cumulative ESA dose
and May 2009 wholesale acquisition costs of $0.014 per U
for EPO and $4.94 per mcg for DARB). The EPO-to-
DARB dose ratio (U EPO:mcg DARB) was calculated
based on mean cumulative EPO dose divided by the mean
cumulative DARB dose. The current analysis included real-
world clinical and hematological outcomes measured
during the therapeutic duration, defined as the patient-
specific ESA treatment duration (the time from first to last
ESA dose) plus the patient-specific mean time between all
ESA doses. The clinical outcomes reported during the
therapeutic duration included the percentage of patients
requiring blood transfusion and the number of units of packed
red blood cells transfused per study patient. Consistent with
analyses of clinical studies in this area, transfusion utilization
was measured after day 28 following ESA initiation to allow
time for the ESA treatment to be effective [7, 13]. Changes in
Hb levels over baseline were determined at ESA treatment
weeks 4, 8, 12, and 16. To account for the potential impact
of transfusions on Hb levels, only transfusion-independent
Hb measures (defined as those occurring ≥28 days after a
transfusion) were analyzed.
Data were summarized by descriptive statistics (means,
standard deviations, counts, and percentages) and compared
using Kruskal–Wallis and chi-square tests for continuous and
categorical variables, respectively. Statistical tests were two-
tailed. All statistical analyses were conducted using SAS
version 9.1 [14].
Results
Baseline characteristics
The current analysis included 540 patients treated in 44
clinical centers, of whom 420 were initiated on EPO
160 Support Care Cancer (2012) 20:159–16540,000 U and 120 were initiated on DARB 500 mcg (Fig. 1).
Observed baseline characteristics were similar between the
EPO and DARB cohorts except for iron supplementation
(Table 1). Mean patient age at treatment initiation was
approximately 64 years, and more than 60% of patients were
female. Mean patient weight was close to 75 kg, and mean
baseline Hb level approximated 10 g/dL. Breast and lung
cancer were the most commonly reported cancer types. Most
patients were undergoing chemotherapy-only regimens with a
similar distribution of platinum and non-platinum-based
chemotherapy. Only 3% of patients had a transfusion within
28 days of initiating an ESA, and a significantly lower
proportion of EPO patients had received iron supplementation
(11.4% EPO vs. 20.0% DARB, p=0.015).
ESA dose and treatment patterns
On average, treatment duration was similar between cohorts
(60.9 days EPO, 61.8 days DARB; p=0.888). The mean
administered EPO dose per injection was 41,979 U and
DARB dose was 488 mcg. The mean cumulative ESA dose
was 295,058 U and 1,750 mcg for EPO and DARB
patients, respectively, resulting in an EPO-to-DARB dose
ratio of 169:1 (U EPO:mcg DARB). Compared to patients
initiated on DARB, those initiated on EPO had a
significantly higher number of Hb determinations during
treatment (7.7 EPO vs. 5.9 DARB, p<0.001); however,
DARB patients experienced a significantly higher number
of office visits during ESA treatment (6.7 EPO vs. 8.1
DARB, p=0.005) (Table 2).
Clinical and economic outcomes
Patients administered EPO experienced more favorable
changes in Hb from baseline (Fig. 2) compared to those
administered DARB. Increases in Hb levels from baseline
were consistently higher in the EPO group compared to the
DARB group through week 12, with statistical significance
at weeks 4 (0.6 g/dL EPO vs. −0.1 g/dL DARB, p<0.001)
and 12 (0.6 g/dL EPO vs. 0.1 g/dL DARB, p=0.032).
n=569 
Less than 2 ESA 
treatments: 96 (16.9%) 
Less than 2 ESA 
treatments: 45 (26.8%) 
n=567 
No post baseline Hb or Hb 28 days 
after transfusion: 2 (0.4%) 
ESA Polytherapy: 16 (2.7%) 
No baseline Hb: 2 (0.4%) 
n=585  n=170 
Initial dose other than 500 
mcg: 534 (75.9%) 
Initial dose other than 
40,000 U: 67 (10.3%) 
n=168 
ESA Polytherapy: 2 (1.2%) 
n=168 
No baseline Hb: 0 (0%) 
n=471  n=123 
n=469 
No post baseline Hb or Hb 28 days 
after transfusion: 1 (0.8%) 
n=122 
n=420 
Radiotherapy only or  
non-specified: 2 (1.6%) 
n=120 
Radiotherapy only or  
non-specified: 49 (10.4%)  
n=652  n=704 
Patients initiated on ESA therapy 
between 
January 1, 2006 and May 8, 2009
N=1,356   
B R A D O P E
Fig. 1 Patient disposition—EPO 40,000 U or DARB 500 mcg. U Units, mcg micrograms, ESA erythropeiesis-stimulating agent, Hb hemoglobin,
EPO epoetin alfa, DARB darbepoetin alfa
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between day 28 to end of study was significantly lower in
the EPO-treated group when compared to the DARB-treated
group (13.9% EPO vs. 22.5% DARB, p=0.026). Similarly,
blood utilization was lower in the EPO- vs. DARB-treated
patients (number of units transfused/study patient: 0.4 EPO
vs. 0.7 DARB, p=0.020). The mean number of units
transfused per transfused patient was similar for both ESA
cohorts (Table 3).
The mean cumulative ESA cost was significantly lower in
patients treated with EPO than in patients treated with DARB
($4,261 EPO vs. $8,643 DARB, p<0.0001) (Fig. 3).
Discussion
This analysis employed data from the DOSE registry, a
prospective, observational study of actual clinical practice
and associated clinical and economic outcomes. This study
provides evidence that clinical outcomes associated with
ESA initiation of EPO 40,000 U or DARB 500 mcg are
consistent with data from previous randomized clinical
trials [7, 13]. Moreover, as observed in other studies, this
study indicates that ESA costs with EPO are substantially
lower per treatment episode than those involving treatment
with DARB [9–11].
Baseline characteristics EPO DARB P-value
Number of patients 420 120
Mean age, years (SD) 63.5 (12.4) 64.3 (12.6) 0.532
Female gender, n (%) 253 (60.2) 78 (65.0) 0.345
Mean weight, kg (SD) 74.5 (17.5) 77.6 (19.9) 0.210
Mean baseline Hb, g/dL (SD) 10.3 (0.89) 10.1 (0.96) 0.215
Distribution of primary cancer, n (%) 0.136
Breast 85 (20.2) 20 (16.7)
Lung 114 (27.1) 36 (30.0)
Gastrointestinal 74 (17.6) 14 (11.7)
Hematologic 37 (8.8) 7 (5.8)
Other/not specified 110 (26.2) 43 (35.8)
Therapeutic treatment, n (%) 0.439
Radiation and chemotherapy 46 (11.0) 18 (15.0)
Platinum-based chemotherapy 189 (45.0) 54 (45.0)
Non-platinum-based chemotherapy 185 (44.0) 48 (40.0)
Receiving iron supplementation, n (%) 48 (11.4) 24 (20.0) 0.015
Had a transfusion 28 days before initiating ESA, n (%) 10 (2.4) 4 (3.3) 0.563
Table 1 Baseline characteristics
among patients initiated with
EPO 40,000 U or DARB
500 mcg
Hb hemoglobin, EPO epoetin
alfa, DARB darbepoetin alfa,
ESA erythropoiesis-stimulating
agent, SD standard deviation
Table 2 Treatment patterns among patients initiated with EPO 40,000 U or DARB 500 mcg
EPO DARB P-value
Mean administered dose per injection, (SD) 41,979 U (5,772) 488 mcg (100) NA
Days between injections, mean (SD) 12.0 (8.7) 26.6 (14.9) NA
Overall dose frequency, n (%) NA
QW 209 (49.8) 0 (0.0)
Q2W 161 (38.3) 8 (6.7)
Q3W 50 (11.9) 112 (93.3)
Mean cumulative ESA dose, (SD) 295,058 U (192,387) 1,750 mcg (870) NA
Mean ESA treatment duration, days (SD) 60.9 (35.1) 61.8 (32.3) 0.888
Mean (SD) number of Hb determinations during treatment duration 7.7 (4.9) 5.9 (4.1) <0.001
Mean (SD) number of office visits during treatment duration 6.7 (6.4) 8.1 (6.6) 0.005
EPO epoetin alfa, DARB darbepoetin alfa, ESA erythropoiesis-stimulating agent, SD standard deviation, QW once per week, Q2W once every two
weeks, Q3W once every three weeks
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therapy in treating cancer patients with CIA. In this real-
world assessment, patients initiated with EPO 40,000 U had
lower transfusion rates and greater early Hb increases
compared to patients initiated with DARB 500 mcg. These
findings are consistent with a previously reported random-
ized controlled trial of EPO 40,000 U weekly vs. DARB
200 mcg every 2 weeks, which found that EPO-treated
patients had significantly greater increases in weekly Hb
from week 3 to study end, as well as lower rates of
transfusions and fewer units transfused than DARB-treated
patients [15]. In the current study, 13.9% of EPO-treated
patients were transfused, a result similar to a randomized
controlled clinical trial that reported blood transfusion in
approximately 11% of patients treated with EPO 40,000 U
weekly [13]. Similarly, the current study reported transfusions
in 22.5% of the DARB-treated patients, consistent with the
23% of patients requiring transfusion in the pivotal clinical
study of patients initiated with DARB 500 mcg [7].
The ESA dosing patterns, treatment duration, and dose
ratio results from this analysis were similar to other published
observational studies. Extended dosing administration has
previously been reported [8–12]. Dosing once every 3 weeks
with DARB 500 mcg was approved by the FDA in March
2006, during the data collection period of the DOSE registry,
and the DARB patients in this study reflect this administra-
tion. Furthermore, the dose ratio reported in this study is
comparable to other studies using similar methodologies
(i.e., comparison of cumulative dose) in peer-reviewed
publications [9, 10]. Higher dose ratios have been reported
with arbitrary extensions of treatment duration for calculation
of weekly ESA dose and dose ratio [8, 11]; however, data-
driven analyses of actual ESA administration have provided
a more complete understanding of the dose ratio [9, 10].
This study is the first to report ESA use and costs, using
absolute quantities of ESA administered, based on a
national, prospective, and observational study of actual
care in clinical settings. The finding that CIA patients who
initiated with EPO 40,000 U vs. DARB 500 mcg had
significantly lower drug costs is noteworthy. Although
different methodological approaches have been used to
examine the cost of care per treatment episode, this study of
real-world treatment patterns supports prior retrospective
claims analyses, one of which showed that EPO treatment
had a 29% lower cost of care per treatment episode
compared to DARB treatment [9] and another that
demonstrated a DARB price premium of 52% [10]. The
current finding that EPO costs were 51% less than DARB
costs may be attributable to the greater precision obtained
in this prospective assessment. For this analysis, ESA dose
was obtained at every administration to generate a total
dose per patient and consequently a mean administered
cumulative dose. A budget impact analysis (BIA) of
patients initiated on EPO 40,000 U or DARB 500 mcg
reported similar ESA drug costs based on a frequency-
adjusted DARB dose with a mean administered EPO dose
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Fig. 2 Mean hemoglobin (Hb) change from baseline among patients
initiated with EPO 40,000 U or DARB 500 mcg
Table 3 PRBC transfusions among patients initiated with EPO 40,000 U or DARB 500 mcg
EPO DARB P-value
Day 28 to EOS, n
a 360 120
Patients requiring PRBC transfusions, n (%) 50 (13.9) 27 (22.5) 0.026
Mean (SD) number of units transfused per transfused patient 2.7 (1.68) 3 (1.45) 0.223
Mean (SD) number of units transfused per study patient 0.4 (1.12) 0.7 (1.42) 0.020
EPO epoetin alfa, DARB darbepoetin alfa, PRBC packed red blood cells, EOS end of study, SD standard deviation
aPatients with available data from day 28 to EOS were reported in this table
Support Care Cancer (2012) 20:159–165 163(without frequency adjustment) as a base case [16]. The
frequency-adjusted DARB dose in the BIA was 375.6 mcg
which contrasts with mean administered DARB dose of
487.6 mcg in the present study and could account for
differing cost evaluations.
Although the design of the DOSE registry has facilitated
the report of a national, real-world comparison between
EPO and DARB, several limitations are acknowledged.
First, this analysis reflects the results from patients initiated
on specific fixed-dose regimens. With heterogeneity of
clinical practice, these patients represent a subset of the
total population. Interestingly, as shown in Fig. 1, compared
to the EPO cohort, a larger proportion of the registry DARB
patients were excluded from this analysis because they
were not initiated on the FDA-approved fixed dosing
regimen. Future analyses will assess the variation of clinical
practice and its association with outcomes.
Another area of uncertainty arises from the assessment
of patients receiving iron supplementation before ESA
initiation. Results show that more DARB patients received
iron therapy, and it is possible that this difference may have
been associated with hematologic outcomes during the
follow-up period. Further research is necessary to examine
these differences in iron utilization at baseline and the
potential impact on hematologic outcomes and costs.
Thisanalysisfocusedonahighvisibilitycostcomponent—
cost of ESAs. Although modest differences in healthcare
utilization are reported in this study, costs have not been
ascribed to them. EPO patients had more Hb determinations
during treatment duration but fewer office visits than DARB
patients; however, the magnitude of the utilization differences
suggest that the overall cost difference between patients
treated with EPO and those treated with DARB are not
appreciably affected by these differences. Because the DOSE
registry did not collect detailed data on the reason for each
office visit, which may have included visits for chemotherapy
or other adjuvant therapy, an explanation for these differences
is not readily available. Nevertheless, it is conceivable that the
greater number of office visits among DARB patients may
translate into higher costs among that cohort. Thus, reporting
only drug costs may underestimate the total healthcare cost
differences between the cohorts.
Conclusion
Among ESA-treated cancer patients with CIA, this
analysis provided a prospective, real-world comparison
of dosing in patients initiated with EPO 40,000 U vs.
DARB 500 mcg. Compared to DARB patients, EPO
patients had greater Hb improvements consistently
throughout treatment and a lower proportion of EPO
patients underwent transfusions. The dose ratio of 169:1
(U EPO:mcg DARB) was similar to previously published
results. The cumulative ESA cost of EPO was 51% less
when compared to DARB. Further research is warranted to
extend this analysis to those patients receiving ESA regimens
other than those presented here.
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